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Background: Gastrointestinal stromal tumor (GIST) is known for its wide variability in biological behaviors and it is
difficult to predict its malignant potential. The aim of this study is to explore the characteristics and prognostic
factors of GIST.
Methods: Clinical and pathological data of 497 GIST patients in our center between 1997 and 2012 were reviewed.
Results: Patients were categorized into very low-, low-, intermediate- and high-risk groups according to modified
National Institutes of Health (NIH) consensus classification system. Among the 401 patients untreated with imatinib
mesylate (IM), 5-year overall survival (OS) in very low-, low-, intermediate- and high-risk groups was 100%, 100%,
89.6% and 65.9%; and 5-year relapse-free survival (RFS) was 100%, 98.1%, 90.9% and 44.5%, respectively. Univariate
analysis revealed that sex, tumor size, mitotic rate, risk grade, CD34 expression, and adjacent involvement were
predictors of OS or RFS. COX hazard proportional model (Forward LR) showed that large tumor size, high mitotic
rate, and high risk grade were independent risk factors to OS, whereas high mitotic rate, high risk grade and
adjacent organ involvement were independent risk factors to RFS. The intermediate-high risk patients who received
IM adjuvant therapy (n = 87) had better 5-year OS and RFS than those who did not (n = 188) (94.9% vs. 72.1; 82.3%
vs. 56.3%, respectively). Similarly, advanced GIST patients underwent IM therapy (n = 45) had better 3-year OS and
1-year progression-free survival (PFS) than those who didn’t (n = 42) (75.6% vs. 6.8%; 87.6% vs. 12.4%, respectively).
Conclusions: Very low- and low-risk GISTs can be treated with surgery alone. Large tumor size, high mitotic rate,
high risk grade, and adjacent organ involvement contribute to the poor outcome. IM therapy significantly improves
the survival of intermediate-high risk or advanced GIST patients.
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Gastrointestinal stromal tumor (GIST) is the most com-
mon mesenchymal neoplasm in the gastrointestinal (GI)
tract [1]. Mazur and Clark [2] first introduced the concept
of “stromal tumor” in 1983. Advance in pathology, immu-
nohistochemistry and molecular biology in recent years has
greatly improved the diagnosis of GIST. It is now consid-
ered that GISTs arise from interstitial Cajal cells (ICCs),
expressing CD117 (product of c-kit proto-oncogene), and
harboring c-kit or platelet-derived growth factor receptor
alpha (PDGFRA) gain-of-function mutation [3-5].* Correspondence: caohuishcn@hotmail.com
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unless otherwise stated.GIST is known for its wide variability in biological
behaviors and it is difficult to predict its malignant po-
tential [6,7]. Tumor size, mitotic rate and tumor site
are considered as the most important prognostic pa-
rameters for patients after surgery [8]. However, nei-
ther small size nor low mitotic rate could exclude
malignant potential [9]. On the other hand, some enor-
mous tumor with high mitotic rate could also achieve
long-term survival, even without adjuvant therapy [10].
The post-operation outcome of GIST is highly variable,
with 5-year survival rate ranging from 48% to 80%
[11,12]. The variability is mainly due to the introduction
of a tyrosine kinases inhibitor (TKI), imatinib mesylate,
which was used in metastatic/recurrent GISTs since 2000td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ago [13,14].
The purpose of this study is to share our latest 15 years
of experience and to explore the prognostic factors of
GISTs.Methods
The clinicopathological and follow-up data of 497 oper-
able GIST patients admitted to Department of General
Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao
Tong University between 1997 and 2012 were reviewed.
Each diagnosis of “GIST” was confirmed by postoperative
histopathology and immunohistochemistry assay (IHCA).
The results of histopathological features and IHCA
findings of every case were reviewed by 2 experienced
pathologists. Those diagnosed as “gastrointestinal stromal
mesenchymal tumor” prior to 2000 were re-examined by
IHCA to confirm the diagnosis of GIST. The tumors were
categorized into very low, low, intermediate and high risk
groups according to the modified NIH risk classification
criteria [7] (Table 1). Only the cases with complete med-
ical records and pathological data were involved in present
study. The following parameters were reviewed and
analyzed: age, sex, clinical presentation, surgical detail,
tumor site, tumor size, mitotic rate, IHCA (CD117,
CD34, vimentin, smooth muscle actin (SMA), S-100,
Discovered On GIST 1 (DOG1)), TKI therapy and out-
come. Survival outcome in terms of overall survival
(OS), relapse-free survival (RFS), and progression-free
survival (PFS) were assessed. OS was defined as the
period from surgery to the last follow-up or death. RFS
was defined as the period from surgery to the time of
clinical or radiological evidence of disease relapse. PFS
in patients who had metastatic or recurrent disease






Very low risk <2 <=5 Any
Low risk 2.1-5.0 <=5 Any
2.1-5.0 >5 Gastric
Intermediate risk <5 6-10 Any
5.1-10 <=5 Gastric




2.1-5.0 >5 Non gastric
5.1-10.0 <=5 Non gastric
HPF = high power field.was diagnosed to clinical or radiological evidence of
progression or death.
All patients provided written informed consent for their
information to be stored in the hospital database, and we
obtained separate consent for use of research. Study ap-
proval was obtained from independent ethics committees
from Ren Ji Hospital, School of Medicine, Shanghai Jiao
Tong University. The study was undertaken in accordance
with the ethical standards of the World Medical Associ-
ation Declaration of Helsinki.
χ2 test and Fisher’s exact test were performed to analyze
qualitative parameters and Kaplan-Meier method with log
rank test was used for postoperative survival analysis. Inde-
pendent factors were identified in multivariate analysis by
COX proportional hazard analysis with forward selection at
P < 0.05. Odds ratios (ORs) and 95% confidence intervals
(CIs) were determined using unconditional multiple logistic
regression models. Two-sided P values of 0.05 or less were
considered to indicate statistical significance.
Results
The incidence of GIST ranges from 11 to 15 per million
per year [15-18]. Growing evidence indicates the incidence
is considerably underestimated [19,20]. The number of
GIST patients admitted to our center is on the rise. In the
past two year, it has approached 100 cases a year (Figure 1).
Clinical and pathological characteristics
Total 497 GIST patients were involved in present study,
with a median age of 60 years (range 23–90) and 55.9%
was male. Stomach and small bowel were the most com-
mon sites of primary disease (59.0% and 22.5%, respect-
ively). The most common clinical presentation was
abdominal discomfort, followed by GI bleeding. Distri-
bution of risk groups: 8.0%, very low; 36.4%, low; 15.7%,
intermediate; and 39.8%, high risk. IM adjuvant therapy
was given to 96 of the patients to prevent disease
relapse. Recurrence or metastases were observed in 89
patients during the follow-up period. Among which, IM
was used to control disease in 46 patients.
Of all the cases, 87.3% was CD117 (+); 80.3%, CD34 (+);
23.6%, SMA (+); and 21.5%, S-100 (+). DOG1 was a newly
developed IHCA marker, which was positive in 139 out of
149 cases (93.3%). The diagnosis of GIST in patients pre-
sented as both CD117 and DOG1 negative was confirmed
by detection of mutation in c-kit/PDGFRA gene. Their
clinical and pathological characteristics are listed in Table 2.
Lymph node metastasis was detected in 5 out of 497
cases (1.01%); clinical and pathological characteristics of
these 5 cases were described in Table 3.
Survival analysis on patients without IM adjuvant therapy
Given the fact that imatinib is an effective drug on GIST,
the first survival analysis was based on the population of
Figure 1 Annual number of newly admitted GIST patient since 1997.
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fore, 401 patients with operable GIST were enrolled in the
cohort, with a median duration of 50 months (range, 7–187
months). Recurrence or metastasis occurred in 79 patients
(19.7%). The abdominopelvic cavity was the most common
site of metastases (51 cases), followed by liver (22 cases),
lung (3 cases), vertebral column (1 case), umbilicus (1 case),
and fossa axillaris (1 case). Forty-five patients died of GIST
progression, and 4 died of other diseases. The 1-, 3-, 5-year
OS of 401 GISTs was 97.7%, 92.6% and 84.8%, respectively;
The 1-, 3-, 5-year RFS was 93.2%, 82.1% and 77.4%,
respectively.
The 1-, 3-, 5-year OS according to risk grade was: 100%,
100%, 100% (very low risk); 100%, 100%, 100% (low risk);
100%, 97.8%, 89.6% (intermediated risk); 93.5%, 80.8%,
65.9% (high risk), respectively (Figure 2).
The 1-, 3-, 5-year RFS according to risk group was:
100%, 100%, 100% (very low risk); 100%, 100%, 98.1%
(low risk); 100%, 93.8%, 90.9% (intermediated risk); 80.6%,
53.1%, 44.5% (high risk), respectively (Figure 3).
Univariate analysis revealed that male gender, non-
gastric origin, larger tumor size, higher mitotic rate, higher
risk grade, CD34 negative expression, and adjacent organ
involvement contributed to poorer outcome (lower OS
and RFS), whereas age and expression of CD117, SMA,
and S-100 were not associated with prognosis (see Table 4
and Additional files 1 and 2).
Multivariate analysis by Cox proportional hazards
regression (Forward LR) model indicated that tumor
size, mitotic rate, and risk grade were independent risk
factors to OS for GISTs, and that mitotic rate, risk
grade, and adjacent involvement were independent risk
factors to RFS (Tables 5 and 6).Survival analysis of patients received IM therapy
From 2007 to 2012, 87 patients with intermediate-high risk
GIST received IM adjuvant therapy after radical resection
(Adjuvant group). Compared with those patients who
were with same risk GIST (intermediate-high risk)
while were not given IM adjuvant therapy (Non-adjuvant
group, n = 188), adjuvant group had better 5-year RFS
(82.3% vs. 56.3%, P < 0.001) and 5-year OS (94.9% vs.
72.1%, P = 0.001) (Figure 4). In addition, there was no
statistical difference in other clinicopathological fea-
tures (sex, age, tumor site, tumor size, mitotic rate, risk
grade, etc.) between the two groups (see Additional file 3),
indicating that these features had no impact on the ef-
fect of IM.
In the cohort, 87 patients developed recurrence of metas-
tasis after surgery for the primary disease. Among them,
c-kit/PDGFRA mutation status was screened in 39 patients.
Their mutational characteristics were demonstrated in our
previous report [21]. Mutations in c-kit exon 11, c-kit exon
9, and PDGFRA exon 18 were identified in 29, 4, and 1 pa-
tients, respectively. And the rest 5 GISTs showed c-kit and
PDGFRA wild type. Among all the 87 advanced GIST pa-
tients, 45 (including 33 c-kit mutant GISTs, 5 wild-type
GISTs, and 7 GISTs with unknown mutation type) were
treated with IM, and the other 42 didn’t undergo any TKI
therapy (10 due to personal reasons and the rest were cases
prior to 2005). There was significant difference in outcome
between the two groups: patients underwent postoperative
IM treatment had better 1-, 3-year OS than those untreated
with IM (97.6% and 75.6% vs. 58.7% and 6.8%, respectively,
P < 0.001). IM therapy also improved 1-year progression-free
survival (PFS) of these patients (87.6% vs. 12.4%, P < 0.001)
(Figure 5).
Table 3 Clinical and pathological characteristics of 5 GIST pat
Case Sex Age Primary site Tumor size Mitotic rate
per 50HPF
MLN/TLN
1 M 60 S 8 23 2/4
2 M 58 G 5 12 1/2
3 F 59 G 5.5 <5 4/4
4 F 70 G 9 8 1/9
5 M 31 D 18 <5 2/2
S = small intestine; G = stomach; D = duodenum MLN = metastatic lymph nodes; T








Primary site of tumor, n (%)
Stomach 293 (59.0)
Duodenum 31 (6.2)
Small bowel 112 (22.5)
Large bowel 4 (0.8)
Rectum 21 (4.2)
Esophagus 3 (0.6)
Other (omentum, mesenterium and retroperitoneum ) 33 (6.6)
Clinical manifestation, n (%)
Abdominal discomfort 184 (37.0)
GI bleeding 142 (28.6)
Diagnosed at physical examination 81 (16.3)
Abdominal mass 14 (2.8)




As adjuvant therapy for primary disease 96
As therapy for advanced disease (recurrent, metastatic,








*DOG1 was examined in 165 cases.
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Although the incidence of GISTs is rising in the oriental
population, available document on this area is still lim-
ited, especially studies with large sample size in a single
center. This study reviewed the clinical and pathological
features of 497 GIST cases in Shanghai Ren Ji Hospital
to explore the prognostic factors of the disease.
GISTs represent 80% of mesenchymal tumor of the di-
gestive tract and constitute 5% of all sarcoma [22]. It
had been reported that the annual occurrences of GIST
were 11–15 per million people [15-18]. However, grow-
ing evidences have proved that the incidence of GISTs is
seriously underestimated. Learn from the studies of
Abraham et al. [23] and Agaimy et al. [24], we can draw
a conclusion that sub-centimeter GISTs (smaller than 1
cm) are common lesions in stomach. Our epidemiologic
data show the number of newly diagnosed GISTs is on
the fast rise (Figure 1), probably due to the increasing
awareness of the disease in clinicians.
Our data indicate that GIST occurrences culminate
among people in their 50s and 60s. The youngest GIST
patient is a 23-year-old female, who suffered from giant
retroperitoneal GIST and died of recurrent disease 32
months after surgery. The oldest patient is a 90-year-old
male with intermediate-risk gastric GIST and he was
relapse-free at last follow-up, six months after surgery.
Although in most published documents there is no clear
sex predilection [3,25,26], some studies revealed that
there was a slight male predominance [27-29]. Our data
agree with the latter.
GISTs have no specific symptom, increasing the diffi-
culty in early diagnosis and treatment. In our data, con-
sistent with the literature, the most frequent complaint
is abdominal discomfort, which may or may not be ac-
companied by GI bleeding [30,31].
GIST may arise anywhere in the GI tract and also in
extragastrointestinal locations (extragastrointestinal stro-
mal tumor, EGIST), including omentum, mesenterium,
and retroperitoneum [32]. According to our data, the
most common GI location of primary disease was stom-
ach (59.0%), followed by small bowel (22.5%), duodenumients with lymph node metastasis
Mutation IM therapy Outcome
c-kit exon9 Yes Died of disease progression at 33 months
after surgery
not available No DFS at 101 months after surgery
c-kit exon11 Yes DFS at 45 months after surgery
c-kit exon11 Yes DFS at 25 months after surgery
c-kit exon11 Yes Survival with residual disease at 3 months
after surgery
LN = total examined lymph nodes; DFS = Disease-free survival.
Figure 2 Overall survival in 401 GIST patients according to risk class.
Figure 3 Relapse-free survival in 401 GIST patients according to risk class.
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Table 4 Univariate analysis of OS and RFS in 401 GIST patients
Clinicopathological
feature
Group N OS RFS
5-year OS (%) χ2 P-value 5-year RFS (%) χ2 P-value
Gender Male 221 80.2 6.590 0.010 71.6 8.914 0.003
Female 180 90.6 84.4
Age <60 197 85.7 1.573 0.210 77.4 0.011 0.917
≥60 204 84.0 77.4
Tumor site Gastric 241 86.5 1.969 0.161 86.1 18.876 <0.001
Non-gastric 160 82.5 65.3
Tumor size ≤2 cm 51 100 110.281 <0.001 100 146.144 <0.001
2.1-5 cm 178 98.0 94.6
5.1-10 cm 109 80.9 66.8
>10 cm 63 49.2 33.5
Mitotic rate <5/50 HPF 296 95.9 83.348 <0.001 91.2 152.472 <0.001
5-10/50 HPF 44 68.0 55.3
>10/50 HPF 61 54.2 33.7
Risk class Very low 39 100 66.044 <0.001 100 154.234 <0.001
Low 172 99.1 98.1
Intermediate 51 89.6 90.9
High 139 65.9 44.5
CD117 expression Positive 350 83.4 3.315 0.069 76.6 1.401 0.237
Negetive 51 95.1 82.6
CD34 expression Positive 322 87.2 7.564 0.006 80.6 10.777 0.001
Negative 79 75.4 64.3
SMA expression Positive 101 90.6 1.559 0.212 83.2 2.246 0.134
Negative 300 83.2 75.6
S-100 expression Positive 84 88.2 1.377 0.241 74.0 0.529 0.467
Negative 317 83.7 78.5
Adjacent involvement Without 336 92.1 66.176 <0.001 87.2 147.885 <0.001
With 65 53.0 30.8
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EGISTs were found in 6.6% of cases.
Typical GISTs are characterized by positive immuno-
histochemical (IHC) staining of KIT (CD117), a trans-
membrane receptor tyrosine kinase. More recently the
antigen DOG1 has been incorporated in the IHC panel
when CD117 was negative [33]. Our data confirmed the
high specificity and sensitivity of this marker: DOG1 ex-
pression was seen in 139 of 149 GISTs, including 15
CD117 negative ones.Table 5 Multivariate COX regression analysis of OS in 401 GIS
Covariate χ2
Tumor size (> = 10 cm vs. <10 cm) 13.224
Mitotic rate (> = 5/50 HPF vs. <5/50 HPF) 10.619
Risk grade (high risk vs. non-high risk) 4.956Except for some sporadic studies [34], lymph node
metastasis is reported to be extremely rare in GIST,
with incidence ranging from 0 ~ 5% [11,35-37]. Although
lymph node metastasis (LNM) is usually considered as a
morphological feature associated with malignancy and
poor prognosis [38,39], our data do not support this opin-
ion. Three out of the 5 patients with LNM in this study
achieved longer than 2 years’ DFS; one of them, though
untreated with IM, was still disease-free at the latest
follow-up, over 8 years after surgery. This aroused theT patients




Table 6 Multivariate COX regression analysis of RFS in
401 GIST patients





11.841 0.001 2.295 1.430-3.683
Mitotic rate (> = 5/50 HPF
vs. <5/50 HPF)
8.895 0.003 2.406 1.351-4.284
Risk grade (high risk vs.
non-high risk)
26.129 <0.001 11.794 4.579-30.379
Wang et al. BMC Surgery 2014, 14:93 Page 7 of 10
http://www.biomedcentral.com/1471-2482/14/93controversy over the exact impact of LNM on GIST out-
come. Further studies with larger sample size are required
to solve this puzzle. Nonetheless, lymph node dissection
should be considered in case of suspected or confirmed
LNM.
The distribution of very low-, low-, intermediate-, high-
risk groups was 8.0%, 36.4%, 15.7%, and 39.8%, respect-
ively. Compared to most published literature [28,40,41],
the proportion of very low and low risk GIST was much
higher. One reason might be the improved screening
system and early surgery. In addition, clinical study on
minimal invasive procedure (laparoscopic/laparoscopy-
endoscopy cooperative surgeries) for GIST is being con-
ducted in our center, and offers the opportunity of early
operation and further elevated the proportion. Thanks to
the popularity of endoscopy, more and more GISTs can
be determined at small size. In most cases, having the ad-
vantages of small incision and fast recovery, minimal inva-
sive surgery is preferred to traditional open operation.
In our study, the outcome (both OS and RFS) of
IM-naive GIST patients was better than that in mostFigure 4 Effect of treatment with or without postoperative IM adjuva
patients (A: overall survival; B: relapse-free survival).published literature [12,42,43] for the same reasons
mentioned above (higher proportion of low risk GIST).
Nonetheless, the high-risk group still had unsatisfactory
results (5-year OS 65.9%, 5-year RFS 44.5%, respectively).
However, very low- and low-risk GISTs in present study
had rather better prognosis: no relapse was found in very
low risk group; only one case, a rectal tumor 3.5cm in
diameter with mitotic rate of <5/50HPF, occurred recur-
rence in low-risk group.
Prediction of biological behavior of a GIST is essential
for selection of candidates for adjuvant therapy as well
as determination of the frequency and intensity of post-
operative surveillance. However, accurate prediction is
often a difficult job. It has been widely accepted that
tumor size, mitotic rate, and anatomic site are the most
important factors influencing the prognosis of GISTs [8].
These factors form the basis for consensus risk classifi-
cation. Our study reveals that risk grade and mitotic rate
were independent prognostic factors of both OS and
RFS, while tumor size and adjacent organ involvement
was independent predictor of OS and RFS, respectively.
Mitotic rate was described as a vital indicator for GIST
staging and consequential choice of surgical and target
therapeutic approach [44,45], its value in prognosis pre-
diction was confirmed again in our study. It’s worth
mentioning that there is a difficulty in reproducibility
among examiners when determining the mitotic rate
[44]. Therefore, all specimens should be examined by
specialized experts to decrease the deviation.
In present study, males had lower survival rate than fe-
males (5-yaer OS, 80.2% vs. 90.6%, P = 0.010; 5-year
RFS, 71.6% vs. 84.4%, P = 0.003). This finding was innt therapy on OS and RFS in 275 intermediate-high risk GIST
Figure 5 Effect of treatment with or without post-operation IM therapy on OS and PFS in 87 advanced GIST cases (A: overall survival;
B: progression-free survival).
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ever, no relationship between sex and survival was found
in the multivariate analysis.
Most documents, including our previous study on a
small cohort, didn’t demonstrate correlation between
CD34 expression and GIST patients’ prognosis [49-51].
However, univariate analysis of present study revealed
that CD34 positive GIST patients had better outcome
than CD34 negative patients (5-yaer OS, 87.2% vs.
75.4%, P = 0.006; 5-year RFS, 80.6% vs. 64.3%, P = 0.001).
Yet subsequent multivariate analysis didn’t show relation-
ship between CD34 and patients’ survival. Therefore, fur-
ther studies are required to determine the exact impact of
sex and CD34 on GIST prognosis.
Long-term monitoring has shown that surgery alone is
usually insufficient to control high-risk diseases. Intro-
duction of imatinib has greatly improved the outcome of
GIST. In China, the application of IM as adjuvant ther-
apy was widely accepted not earlier than 2005. Presently,
IM is standard therapy for advanced and primary
intermediate-high risk GISTs (for adjuvant option)
[14]. In present study, IM adjuvant therapy had better
5-year OS and RFS than non-adjuvant group. The limita-
tion of this study is obvious: the selection of candidates
and the interval of adjuvant therapy were not standard-
ized. The follow-up period of adjuvant group was much
shorter than that of non-adjuvant group, which highlighted
the importance of persistent follow-up on those patients.
The exact effect of IM on GIST can only be assessed by
prospective randomized controlled trials with long-term
follow-up, just like Z9001 [52] and SSGXVIII trials [53].
However, our findings still encourage the use of IM adju-
vant therapy.Undoubtedly, residual, recurrent or metastatic GISTs
should be treated with imatinib according to the guide-
lines by European Society for Medical Oncology (ESMO)
[54] or National Comprehensive Cancer Network (NCCN)
[55]. In this cohort, however, some patients with advanced
disease did not undergo IM therapy. Most of the cases
were before 2005, when IM was not available in China. In
present study, late-stage GIST (residual disease) patients
underwent IM therapy had better 3-year OS and 1-year
PFS than those who didn’t (75.6% vs. 6.8%; 87.6% vs.
12.4%, respectively), confirming the effect of IM on ad-
vanced disease.Conclusions
In summary, radical surgery is the treatment of choice
for operable GISTs. Very low- and low-risk diseases can
be treated with surgery alone. Lymph node metastasis is
rare in GIST patients and may not be associated with
poor prognosis. Large size, high mitotic rate, high risk
group, and adjacent organ involvement all contribute to
bad outcome of GISTs. IM therapy significantly im-
proves survival of patients with intermediate-high risk or
advanced GISTs.Additional files
Additional file 1: Univariate analysis of OS. Univariate analysis of
overall survival in 401 GIST patients (a: gender; b: tumor size; c: mitotic
rate; d: CD34 expression; e: adjacent involvement).
Additional file 2: Univariate analysis of RFS. Univariate analysis of
relapse-free survival in 401 GIST patients (a: sex; tumor site; c: tumor size;
d: mitotic rate; e: CD34 expression; f: adjacent involvement).
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characteristics of 275 intermediate-high risk GIST patients according to
whether received post-operation IM adjuvant therapy.
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